免疫疗法
癌症研究
免疫系统
基因敲除
医学
腺癌
肺腺癌
生物标志物
胆固醇
肺
免疫学
CXCR4型
封锁
肿瘤微环境
生物
转移
FOXP3型
平衡
受体
T细胞
肿瘤进展
RNA干扰
小发夹RNA
内科学
肝X受体
抑制器
作者
Min Deng,Sek Man Su,Zhi-Ran Zhai,Tingting An,Yuqing Wang,Ying Yang,Di Mu,Yanjie Wang,Dongyang Tang,Xin Zhang,Xiaoling Li,Elaine Lai‐Han Leung,Xiaoling Xu,Chen Huang,Chu‐Xia Deng
摘要
Immune heterogeneity and metabolic remodeling frequently limit the efficacy of immunotherapy in lung adenocarcinoma (LUAD). To address this challenge, we integrated single-cell and bulk RNA sequencing analyses, pairing machine learning with preclinical models to develop the APOA5-correlated T-cell Signature (ACTsig), which effectively stratifies LUAD patients and predicts immunotherapeutic response. Moreover, We identified apolipoprotein A-V (APOA5) as a previously unrecognized tumor suppressor linking cholesterol homeostasis to the tumor immune ecosystem. Mechanistically, APOA5 deficiency induced intracellular cholesterol accumulation and MIF production. Cholesterol depletion and replenishment established a causal role for cholesterol accumulation in regulating MIF production, while MIF knockdown reversed APOA5-loss-induced T-cell exhaustion and recombinant MIF restored the phenotype. Meanwhile, CXCR4 blockade rescued APOA5-loss-induced T-cell exhaustion, supporting the functional involvement of the MIF receptor CXCR4 in this immunosuppressive phenotype. Finally, in silico drug screening identified fenofibrate, which, in combination with anti-PD-1 therapy, significantly suppressed tumor growth in APOA5-deficient models. Together, these findings establish ACTsig as a predictive biomarker for immunotherapy response and reveal an APOA5-cholesterol-MIF-CXCR4 axis underlying T-cell exhaustion.
科研通智能强力驱动
Strongly Powered by AbleSci AI